Search Within

Advanced Practice Providers

  1. "David Chung"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (7)
Groups
  1. Bone Marrow Transplant (29)
  2. Center for Hematologic Malignancies (29)
  3. Department of Medicine (29)
  4. Hematologic Malignancies, Division of (29)
  5. Survivorship Research (29)
  6. CTCR Scholars (23)

More Groups

People
  1. David Chung (29)
  2. Sergio Giralt (25)
  3. Heather Landau (24)
  4. Gunjan Shah (22)
  5. Sean Devlin (18)
  6. Michael Scordo (15)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (4)
  4. 2021 (4)
  5. 2020 (2)
  6. 2019 (2)

More Years

Publications
  1. Blood (15)
  2. Biology of Blood and Marrow Transplantation (4)
  3. Clinical Lymphoma, Myeloma and Leukemia (2)
  4. Transplantation and Cellular Therapy (2)
  5. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (1)
  6. Blood Advances (1)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Elsevier Inc. (8)
  3. American Association for Cancer Research (1)
  4. American Medical Association (1)
  5. American Society for Microbiology (1)
  6. Nature Publishing Group (1)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
    Journal Article

    Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Dysgeusia is associated with higher melphalan pharmacokinetic levels and results in poorer caloric intake and worse symptom burden after autologous stem cell transplantation for multiple myeloma
    Meeting Abstract

    Scordo, M.; Shah, G. L.; Preston, E. V.; Rodriguez, N.; Lin, A.; Maloy, M.; Mastrogiacomo, B.; Carlow, D.; Schofield, R.; Knezevic, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Homebound autologous hematopoietic cell transplantation for plasma cell disorders in an urban setting is safe for patients and preferred by patients and caregivers
    Meeting Abstract

    Landau, H. J.; Shah, G. L.; Reeds, M.; Hilden, P.; Andrejko, M.; Applebaum, A.; Batalha, J.; Cazeau, N.; Chung, D. J.; Cortes, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save